Prevalence of chronic cough and patient characteristics in adults in Spain: A population-based cross-sectional survey
Por:
Domínguez-Ortega J., Plaza V., Li V.W., Fonseca E., Cea-Calvo L., Martin A., Sánchez-Jareño M., Brady J.E., Schelfhout J.
Publicada:
1 abr 2022
Resumen:
Background Chronic cough (CC) represents a significant health burden. This study assessed the prevalence of CC (defined as per international guidelines as cough duration >8 weeks) in Spanish adults and compared characteristics between CC and non-CC cohorts. Methods CC cohorts were compiled using data from adult respondents to the 2020 Spanish cross-sectional online National Health and Wellness Survey (NHWS). Using propensity scores, respondents experiencing CC during their lifetime and the previous 12 months were matched 3:1 to respondents without CC and their health characteristics were compared. The number of Spanish adults affected with CC was estimated using weighted CC prevalence. Results CC during their lifetime or the previous 12 months was experienced by 579 (8.2%) and 389 (5.5%) of 7074 NHWS respondents, of whom 233 (38.5%) and 171 (44.0%), respectively, had physician-diagnosed CC. Based on weighted prevalence rates, lifetime and 12-month CC were estimated to affect approximate to 3.3 million and approximate to 2.2 million Spanish adults, respectively. Relative to the non-CC cohort, the 12-month CC cohort consistently demonstrated poorer health status, poorer mental health, greater healthcare utilization, and lower productivity at work and home. Conclusion This study contributes novel data regarding the prevalence of CC in Spain, suggests that CC is underdiagnosed, and reflects that CC and related comorbidities inflict a significant health burden in the affected population.
Filiaciones:
Domínguez-Ortega J.:
Allergy Department, La Paz University Hospital, IdiPAZ, Madrid, Spain
CIBER of Respiratory Diseases, CIBERES, Madrid, Spain
Plaza V.:
CIBER of Respiratory Diseases, CIBERES, Madrid, Spain
Respiratory Medicine Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain
Medicine Department, University Autonomous of Barcelona (UAB), Barcelona, Spain
Li V.W.:
Cerner Enviza, New York, NY, United States
Fonseca E.:
Merck Co., Inc., Rahway, NJ, United States
Cea-Calvo L.:
Medical Affairs, MSD, Madrid, Spain
Martin A.:
Cerner Enviza, New York, NY, United States
Sánchez-Jareño M.:
Medical Affairs, MSD, Madrid, Spain
Brady J.E.:
Merck Co., Inc., Rahway, NJ, United States
Schelfhout J.:
Merck Co., Inc., Rahway, NJ, United States
All Open Access, Gold
|